Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

NCT03102606 is registered in ClinicalTrials.gov with BeyondSpring Pharmaceuticals Inc. as lead sponsor.

NCT NCT03102606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03102606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 29, 2018
Completion date
February 8, 2021
Enrollment
105 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neutropenia